Modeling anxiety in Parkinson's disease
2015; Wiley; Volume: 31; Issue: 3 Linguagem: Inglês
10.1002/mds.26461
ISSN1531-8257
AutoresMartijn Broen, Sebastian Köhler, Anja J.H. Moonen, Mark L. Kuijf, Kathy Dujardin, Laura Marsh, Irene Hegeman Richard, Sergio Starkstein, Pablo Martínez‐Martin, Albert F.G. Leentjens,
Tópico(s)Restless Legs Syndrome Research
ResumoMovement DisordersVolume 31, Issue 3 p. 310-316 Research Article Modeling anxiety in Parkinson's disease Martijn P.G. Broen MD, Corresponding Author Martijn P.G. Broen MD Department of Neurology, Maastricht University Medical Center, Maastricht, The NetherlandsCorrespondence to: Dr. Martijn P.G. Broen Department of Neurology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands; [email protected]Search for more papers by this authorSebastian Köhler PhD, Sebastian Köhler PhD Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, The NetherlandsSearch for more papers by this authorAnja J.H. Moonen MSc, Anja J.H. Moonen MSc Department of Psychiatry, Maastricht University Medical Center, Maastricht, The NetherlandsSearch for more papers by this authorMark L. Kuijf MD, PhD, Mark L. Kuijf MD, PhD Department of Neurology, Maastricht University Medical Center, Maastricht, The NetherlandsSearch for more papers by this authorKathy Dujardin PhD, Kathy Dujardin PhD Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, FranceSearch for more papers by this authorLaura Marsh MD, Laura Marsh MD Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USASearch for more papers by this authorIrene H. Richard MD, Irene H. Richard MD Departments of Neurology and Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USASearch for more papers by this authorSergio E. Starkstein MD, Sergio E. Starkstein MD School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Western Australia, AustraliaSearch for more papers by this authorPablo Martinez-Martin MD, PhD, Pablo Martinez-Martin MD, PhD Area of Applied Epidemiology, National Center for Epidemiology, and CIBERNED, Carlos III Institute of Health, Madrid, SpainSearch for more papers by this authorAlbert F.G. Leentjens MD, PhD, Albert F.G. Leentjens MD, PhD Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, The Netherlands Department of Psychiatry, Maastricht University Medical Center, Maastricht, The NetherlandsSearch for more papers by this author Martijn P.G. Broen MD, Corresponding Author Martijn P.G. Broen MD Department of Neurology, Maastricht University Medical Center, Maastricht, The NetherlandsCorrespondence to: Dr. Martijn P.G. Broen Department of Neurology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands; [email protected]Search for more papers by this authorSebastian Köhler PhD, Sebastian Köhler PhD Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, The NetherlandsSearch for more papers by this authorAnja J.H. Moonen MSc, Anja J.H. Moonen MSc Department of Psychiatry, Maastricht University Medical Center, Maastricht, The NetherlandsSearch for more papers by this authorMark L. Kuijf MD, PhD, Mark L. Kuijf MD, PhD Department of Neurology, Maastricht University Medical Center, Maastricht, The NetherlandsSearch for more papers by this authorKathy Dujardin PhD, Kathy Dujardin PhD Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, FranceSearch for more papers by this authorLaura Marsh MD, Laura Marsh MD Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USASearch for more papers by this authorIrene H. Richard MD, Irene H. Richard MD Departments of Neurology and Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USASearch for more papers by this authorSergio E. Starkstein MD, Sergio E. Starkstein MD School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Western Australia, AustraliaSearch for more papers by this authorPablo Martinez-Martin MD, PhD, Pablo Martinez-Martin MD, PhD Area of Applied Epidemiology, National Center for Epidemiology, and CIBERNED, Carlos III Institute of Health, Madrid, SpainSearch for more papers by this authorAlbert F.G. Leentjens MD, PhD, Albert F.G. Leentjens MD, PhD Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, The Netherlands Department of Psychiatry, Maastricht University Medical Center, Maastricht, The NetherlandsSearch for more papers by this author First published: 21 December 2015 https://doi.org/10.1002/mds.26461Citations: 15 Funding agencies: The study from which data were used for the present analysis was funded by the Michael J. Fox Foundation for Parkinson Research. Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat ABSTRACT Background The aim of this work was to construct a model for anxiety in PD and compare the relative contributions of PD-specific and -nonspecific general population risk factors for anxiety in this model. Methods Structural equation modeling of associations of risk factors with the anxiety outcome using a cross-sectional data set of 342 patients with PD were used. Results A model with acceptable to good fit was generated that explained 65% of the variance in anxiety scores. A previous history of depression and the severity of the depressive symptoms scored on the Hamilton Depression Rating Scale were the only nonspecific variables with a direct effect on anxiety. The presence of motor fluctuations and disease-related decline in activities of daily living were PD-specific markers of anxiety. Nonspecific risk factors had a greater influence in the model than PD-specific risk factors. Standardized regression coefficients suggested that the Hamilton Depression Rating Scale score was the most important contributor to the variation in anxiety. A post-hoc analysis showed that the effects of the following variables on anxiety levels were fully mediated by depression: sex; family history of depression; previous history of anxiety; cognitive status; difficulties in non-disease-specific activities of daily living; and severity of motor signs. Conclusion In this cross-sectional study, we showed that nonspecific general population risk factors are more important markers for anxiety than PD-specific risk factors. Depression was the most prominent marker. PD-specific markers for anxiety appear to be more situational and related to off periods and disease-specific disturbances of activities of daily living. © 2015 International Parkinson and Movement Disorder Society Supporting Information Additional Supporting Information may be found in the online version of this article at the publisher's web-site. Filename Description mds26461-sup-0001-suppinfo01.docx105.3 KB Supplementary Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. References 1 Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641-1649. 10.1002/mds.22643 CASPubMedWeb of Science®Google Scholar 2 Pontone GM, Williams JR, Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009; 24: 1333-1338. 10.1002/mds.22611 PubMedWeb of Science®Google Scholar 3 Sagna A, Gallo JJ, Pontone GM. Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease. Parkinsonism Relat Disord 2014; 20: 708-715. 10.1016/j.parkreldis.2014.03.020 PubMedWeb of Science®Google Scholar 4 Yamanishi T, Tachibana H, Oguru M, et al. Anxiety and depression in patients with Parkinson's disease. Intern Med 2013; 52: 539-545. 10.2169/internalmedicine.52.8617 PubMedWeb of Science®Google Scholar 5 Beekman AT, Bremmer MA, Deeg DJ, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 1998; 13: 717-726. 10.1002/(SICI)1099-1166(1998100)13:10 3.0.CO;2-M CASPubMedGoogle Scholar 6 Schoevers RA, Beekman AT, Deeg DJ, Jonker C, van Tilburg W. Comorbidity and risk-patterns of depression, generalised anxiety disorder and mixed anxiety-depression in later life: results from the AMSTEL study. Int J Geriatr Psychiatry 2003; 18: 994-1001. 10.1002/gps.1001 CASPubMedWeb of Science®Google Scholar 7 Vink D, Aartsen MJ, Schoevers RA. Risk factors for anxiety and depression in the elderly: a review. J Affect Disord 2008; 106: 29-44. 10.1016/j.jad.2007.06.005 PubMedWeb of Science®Google Scholar 8 Dissanayaka NN, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010; 25: 838-845. 10.1002/mds.22833 PubMedWeb of Science®Google Scholar 9 Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study. Mov Disord 2011; 26: 484-492. 10.1002/mds.23528 PubMedWeb of Science®Google Scholar 10 Leentjens AF, Moonen AJ, Dujardin K, et al. Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors. Neurology 2013; 81: 1036-1043. 10.1212/WNL.0b013e3182a4a503 PubMedWeb of Science®Google Scholar 11 Leentjens AF, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P. Anxiety rating scales in Parkinson's disease: a validation study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale. Mov Disord 2011; 26: 407-415. 10.1002/mds.23184 PubMedWeb of Science®Google Scholar 12 de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 1997; 48: 1277-1281. 10.1212/WNL.48.5.1277 PubMedWeb of Science®Google Scholar 13 Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord 2007; 22: 2314-2324. 10.1002/mds.21844 CASPubMedWeb of Science®Google Scholar 14 Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198. 10.1016/0022-3956(75)90026-6 CASPubMedWeb of Science®Google Scholar 15 Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22: 1077-1092. 10.1002/mds.21333 CASPubMedWeb of Science®Google Scholar 16 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442. 10.1212/WNL.17.5.427 CASPubMedWeb of Science®Google Scholar 17 Fahn S, Elton RL; Members of the UPDRS Committee. Unified Parkinson's Disease Rating Scale. In: S Fahn, CD Marsden, M Goldstein, DB Calne, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Health Care; 1987: 153-163. 10.1111/j.1600-0404.2007.00818.x CASPubMedWeb of Science®Google Scholar 18 Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186. 10.1111/j.1532-5415.2007.01590.x CASPubMedWeb of Science®Google Scholar 19 Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55. 10.1111/j.2044-8341.1959.tb00467.x CASPubMedWeb of Science®Google Scholar 20 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62. 10.1111/j.2044-8341.1959.tb00467.x CASPubMedWeb of Science®Google Scholar 21 Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20): 22-33; quiz, 4–57. PubMedWeb of Science®Google Scholar 22 Starkstein SE, Dragovic M, Dujardin K, et al. Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach. Am J Geriatr Psychiatry 2014; 22: 1410-1417. 10.1016/j.jagp.2013.09.006 PubMedWeb of Science®Google Scholar 23 Byrne BM. Structural Equation Modeling with Mplus: Basic Concepts, Applications, and Programming. New York: Taylor & Francis Group; 2011. Google Scholar 24 Dissanayaka NN, White E, O'Sullivan JD, Marsh R, Pachana NA, Byrne GJ. The clinical spectrum of anxiety in Parkinson's disease. Mov Disord 2014; 29: 967-975. 10.1002/mds.25937 PubMedWeb of Science®Google Scholar 25 Negre-Pages L, Grandjean H, Lapeyre-Mestre M, et al. Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study. Mov Disord 2010; 25: 157-166. 10.1002/mds.22760 PubMedWeb of Science®Google Scholar 26 Calleo JS, Amspoker AB, Sarwar AI, et al. A pilot study of a cognitive-behavioral treatment for anxiety and depression in patients with Parkinson disease. J Geriatr Psychiatry Neurol 2015; 28: 210-217. 10.1177/0891988715588831 PubMedWeb of Science®Google Scholar 27 Mondolo F, Jahanshahi M, Grana A, Biasutti E, Cacciatori E, Di Benedetto P. Evaluation of anxiety in Parkinson's disease with some commonly used rating scales. Neurol Sci 2007; 28: 270-275. 10.1007/s10072-007-0834-9 CASPubMedWeb of Science®Google Scholar 28 Solla P, Cannas A, Floris GL, et al. Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1009-1013. 10.1016/j.pnpbp.2011.02.002 CASPubMedWeb of Science®Google Scholar 29 Bolluk B, Ozel-Kizil ET, Akbostanci MC, Atbasoglu EC. Social anxiety in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 2010; 22: 390-394. 10.1176/jnp.2010.22.4.390 PubMedWeb of Science®Google Scholar 30 Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, García-Sánchez C, Gironell A; Trapecio Group Study. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2008; 23: 1889-1896. 10.1002/mds.22246 CASPubMedWeb of Science®Google Scholar 31 Martinez-Martin P, Falup Pecurariu C, Odin P, et al. Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. J Neurol 2012; 259: 1639-1647. 10.1007/s00415-011-6392-3 PubMedWeb of Science®Google Scholar 32 Foster PS, Drago V, Mendez K, Witt JC, Crucian GP, Heilman KM. Mood disturbances and cognitive functioning in Parkinson's disease: the effects of disease duration and side of onset of motor symptoms. J Clin Exp Neuropsychol 2013; 35: 71-82. 10.1080/13803395.2012.753037 PubMedWeb of Science®Google Scholar 33 Lee WJ, Tsai CF, Gauthier S, Wang SJ, Fuh JL. The association between cognitive impairment and neuropsychiatric symptoms in patients with Parkinson's disease dementia. Int Psychogeriatr 2012; 24: 1980-1987. 10.1017/S1041610212001317 PubMedWeb of Science®Google Scholar 34 Stefanova E, Ziropadja L, Petrovic M, Stojkovic T, Kostic V. Screening for anxiety symptoms in Parkinson disease: a cross-sectional study. J Geriatr Psychiatry Neurol 2013; 26: 34-40. 10.1177/0891988713476368 PubMedWeb of Science®Google Scholar 35 Burn DJ, Landau S, Hindle JV, et al. Parkinson's disease motor subtypes and mood. Mov Disord 2012; 27: 379-386. 10.1002/mds.24041 PubMedWeb of Science®Google Scholar 36 Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34: 465-470. 10.1016/0006-3223(93)90237-8 PubMedWeb of Science®Google Scholar 37 Chen YK, Lu JY, Chan DM, et al. Anxiety disorders in Chinese patients with Parkinson's disease. Int J Psychiatry Med 2010; 40: 97-107. 10.2190/PM.40.1.h PubMedWeb of Science®Google Scholar 38 Gultekin BK, Ozdilek B, Bestepe EE. Social phobia in Parkinson's disease: prevalence and risk factors. Neuropsychiatr Dis Treat 2014; 10: 829-834. PubMedWeb of Science®Google Scholar 39 Calleo J, Williams JR, Amspoker AB, et al. Application of depression rating scales in patients with Parkinson's disease with and without co-occurring anxiety. J Parkinsons Dis 2013; 3: 603-608. PubMedWeb of Science®Google Scholar 40 Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P. The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 2014; 29: 1035-1043. 10.1002/mds.25919 PubMedWeb of Science®Google Scholar Citing Literature Volume31, Issue3March 2016Pages 310-316 ReferencesRelatedInformation
Referência(s)